Formosa Pharmaceuticals Pipeline

Pipeline Overview

Lead Product Candidates

For Inflammation and Pain after Cataract Surgery Treatment| APP13007

Formosa Pharma Ophthalmic Drugs

Through Formosa Pharma’s proprietary APNT nanoparticle formulation technology, APP13007 is expected to provide ophthalmologists and cataract patients with a compelling, effective, and more convenient postoperative anti-inflammatory and pain relief solution.

Kadcyla Biosimilar|TSY-0110

TSY-0110 Breast Cancer ADC
TSY-0110 is a biosimilar of the ADC Kadcyla. Combining the antibody and bioconjugation capabilities from two leading CDMOs in Taiwan, affording excellent biosimilarity to the originator’s product, TSY-0110 aims to be the first-launched and provide HER2+ positive breast cancer patients and health insurance payers with an equally effective and more economical option for treatment.

Ophthalmology Programs

Formosa Pharmaceuticals’ ophthalmic assets are derived from APNT formulation technology, which has the strong potential to address the limitations and disadvantages of currently marketed eye drops. Please refer to our Pipeline to learn more.

Oncology Programs

Formosa Pharmaceuticals’ oncology programs include ADC biosimilars as well as small-molecule NCEs. TSY-0110 is a biosimilar of Kadcyla, which is designated as the one of the second-line therapies for HER2-positive breast cancer by NCCN.

Anti-infective Programs

Formosa Pharmaceuticals’ Anti-infective Program, TSY-0210 possesses a broad and respected antibacterial spectra, including nosocomial infections and resistant strains. TSY-0210 addresses 9 of top 22 priority pathogens designated by WHO and CDC.

Drug Development through APNT Nanoparticle Formulation Technology

APNT has been demostrated its applicability and benefit to formulation development in following compound classes or indications and dosage forms.
Compound Class or Indication Dosage forms Benefits to the Asset
* Analgesic
* Anti-allergy
* Anti-fungal
* Anti-viral
* Antibiotic
* Corticosteroids
* Gastritis
* Oncology
* Respiratory
* Inhaler
* Ophthalmic
* Oral
* Topical
* Improved Bioavailability
* Stable formulation
* Applicable to aseptic formulations
* Patent strategy ( life-cycle management)

Development Pipeline

Scroll to Top